1. If we wanted to produce human insulin or human blood clotting factor in bacteria, what problems might we encounter?
2. If a patient had a defective gene for insulin or blood clotting factor and we wanted to replace the patient's defective gene with a functioning gene for human insulin or blood clotting factor, what problems might we encounter?
3. Do you expect that somatic cell gene therapy and germ-line gene therapy for the same disease will be equally difficult?